Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany
Silence Therapeutics agreed to be acquired by Merck KGaA, Darmstadt, Germany in an all-cash deal valued at approximately $1.3 billion in equity value ($1.1 billion enterprise value). Shareholders will receive $20.00 per ADS, a 130% premium to the October 16, 2026 close and an 82% premium to the 30-day VWAP of $10.99. The deal, a result of a competitive sale process, follows potentially best-in-class Phase 2 polycythemia vera data for Divesiran, which Merck KGaA intends to advance into Phase 3.
Key figures
- Deal Value Usd
- $1.3 billion
- Offering Price
- 20
- Vwap 30day
- $10.99
- Expected close
- Q1 2027
- Enterprise value
- $1.1 billion
- Per ordinary share
- $6.6667
- Premium to 30day vwap
- 82%
- Premium to prior close
- 130%
- Support agreement voting power
- 14%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.